{
    "nct_id": "NCT05086497",
    "official_title": "Whole-Brain Spectroscopy Guided Personalized Mapping of Transducer Arrays for Glioblastoma Patients Receiving Tumor Treating Fields",
    "inclusion_criteria": "* Adult population â‰¥ 22 years\n* Histologically confirmed diagnosis of GBM or molecular GBM according to c-IMPACT NOW criteria\n* Have undergone maximal safe surgical resection followed by either standard full course radiation of 6000 cGy in 6 weeks or a hypofractionated course of 4000 cGy in 3 weeks\n* 3 Harboring any genotype profiles (MGMT promoter methylation or unmethylation and/or isocitrate dehydrogenase (IDH) mutant or IDH wild-type)\n* Possessing adequate hematological, hepatic and renal functions\n* Willingness to receive TTFields\nHealthy volunteers allowed\nMust have minimum age of 22 Years",
    "exclusion_criteria": "* Presence of infra-tentorial GBM\n* Pregnancy\n* Significant co-morbidities at baseline which would prevent maintenance TMZ treatment\n* Active implanted medical device, a skull defect (such as missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators,pacemakers, defibrillators and programmable shunts. , other implanted electronic devices in the brain.\n* Sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.\n* Presence of significant hemorrhage in and around the tumor bed that may potentially degrade the image quality.",
    "miscellaneous_criteria": ""
}